Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INCB 54329

Next Previous
X
Search
Drug Profile

INCB 54329

Alternative Names: INCB-054329; INCB-54329

Latest Information Update: 12 Oct 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Class Acenaphthenes; Antineoplastics; Aza compounds; Isoxazoles; Ketones; Pyridines; Small molecules
  • Mechanism of Action BRD2 protein inhibitors; BRD3 protein inhibitors; BRD4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haematological malignancies; Pancreatic cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 12 Oct 2021 Chemical structure information added
  • 01 Apr 2019 Incyte Corporation completes an expanded-access programme for Renal cell cancer (Metastatic disease) in USA (NCT03896815)
  • 30 Oct 2017 Adverse events data from a phase I/II trial in Solid tumours and Haematological malignancies presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top